SecBot SecBot

MGNX drug pipeline

MACROGENICS INC · 5 rated drugs
$2.17
−1.4% 1-day · Nov 16
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
±2.7%
1-day, median of 5 events
IV rank
No data
No current options data
Rated drugs
5
1 mixed · 4 neutral
Phase 3 trials
0
0 with results posted

Drugs

soonest catalyst first
◆ mixed
Impact
PhasePhase 2
Time to marketUnknown — the drug is in Phase 2 with no registrational trial announced. If the lower-dose LINNET data in H1 2027 is compelling enough to support a registrational path, a potential BLA filing would likely be at least 2-3 years away.

lorigerlimab Updated Oct 26

What to watch

The next catalyst is updated LINNET results at a lower 3 mg/kg Q3W dose, expected in H1 2027, positive data could de-risk the safety profile and support registrational discussions, while further safety issues or weak efficacy would likely impair the asset's value. Meanwhile, watch for partnership/licensing interest in lorigerlimab or the broader pipeline (MGC026), and monitor the stock's elevated ~11% short interest (~10.9 days to cover) which could amplify moves on binary events.

Bull case
  • 25% confirmed ORR and 44% DCR in clear cell gynecologic cancer, a difficult-to-treat tumor type with limited options, is a meaningful early efficacy signal (source: MacroGenics Oct 26, 2026 press release via GlobeNewswire)
  • The bispecific PD-1×CTLA-4 design is differentiated from combination checkpoint therapy, potentially offering better tolerability and tumor-localized activity (source: MacroGenics pipeline page)
  • Company has $327M cash runway through 2028, providing ample funding to advance lorigerlimab and other pipeline assets without near-term dilution (source: MacroGenics Q2 2026 earnings release)
Bear case
  • 49% Grade ≥3 treatment-related adverse event rate and one Grade 5 (fatal) TRAE in the LINNET study raise significant safety concerns; 24% of patients discontinued due to TRAEs (source: MacroGenics Oct 26, 2026 press release analysis)
  • The FDA placed a partial clinical hold on the LINNET study in February 2026 after a patient death, which was only lifted in April 2026, regulatory scrutiny is elevated (source: FDA catalyst data, Feb-Apr 2026)
  • MacroGenics already discontinued lorigerlimab in mCRPC after the LORIKEET study failed to support further development, narrowing the addressable market (source: MacroGenics Q3 2025 earnings release)
● neutral
Impact
PhasePhase 1
Time to marketUnknown — still in Phase 1; if successful, Phase 2/3 trials and regulatory review would take several years

MGC026 Updated Oct 23

What to watch

Watch for the early 2027 initiation of the MGC026 + pembrolizumab front-line SCCHN combo study and the mid-2027 Phase 1 data update. The stock's $2.25 price vs. $8 mean analyst target suggests the market is pricing in significant pipeline risk. Monitor competitive B7-H3 ADC data from I-DXd and HS-20093 as benchmarks.

Bull case
  • 27% best ORR (6/22) in heavily pretreated SCCHN compares favorably to competing B7-H3 ADCs like I-DXd (14%) and HS-20093 (17%) per the company's 8-K filing
  • Zero treatment-related discontinuations, ILD, or ocular toxicity, a clean safety profile that supports combination therapy with checkpoint inhibitors
  • Mean analyst price target of $8 vs. current ~$2.25 stock price implies ~278% upside, with 9 of 14 analysts at Buy/Strong Buy
Bear case
  • Phase 1 data are preliminary with small sample sizes (n=22 in SCCHN expansion); response rates may change with full enrollment
  • B7-H3 ADC space is increasingly competitive with multiple programs (I-DXd from Daiichi Sankyo, HS-20093 from Hansoh Pharma, YL201 from YL Biologics) advancing
  • MacroGenics is pre-revenue with no approved products; reliance on pipeline success and capital markets for funding
● neutral
Impact
PhasePhase 1
Time to marketIf MGC028 advances successfully through Phase 1 dose optimization and into Phase 2/3 trials, potential approval would be several years away, likely 2029 or later under an optimistic scenario. The drug is currently in Phase 1 dose optimization.

MGC028 Updated Nov 15

What to watch

MGC028 is now in dose optimization after completing Phase 1 dose escalation. The next data readout could come in 2027 once both dose-level cohorts mature, but no date is set. Interim results were already presented at ESMO 2026; the market reaction to those data was not a major stock mover since MGC028 is one of several early-stage assets at MacroGenics. Watch for any future clinical update or partnership interest around the ADAM9 target.

Bull case
  • ADAM9 is overexpressed in multiple high-incidence cancers (pancreatic, gastric, lung adenocarcinoma, squamous-cell lung cancer), offering a large addressable patient population if the drug works.
  • MGC028 uses a Topo1 inhibitor payload, the same class as Enhertu and Trodelvy (both billion-dollar ADCs), potentially offering a favorable efficacy/toxicity profile.
  • Phase 1 dose escalation completed successfully with a lead indication selected for dose optimization, suggesting tolerable safety and early signs of activity.
Bear case
  • MGC028 is still in early Phase 1 (dose optimization), many years from potential approval; the vast majority of Phase 1 ADCs fail or are deprioritized.
  • MacroGenics has no approved products and depends on partnership revenue, which is lumpy (Q3 2026 revenue fell to $18.7M from $53M a year ago).
  • The ADAM9 target is not clinically validated; no ADAM9-directed ADC has been approved, creating biological uncertainty.
● neutral
Impact
PhasePhase 1
Time to marketIf successful through all clinical phases, potential approval would likely be many years away (approximately 2029-2031 at the earliest), as the drug is just entering Phase 1 dose-escalation studies.

MGC030 Updated Nov 15

What to watch

MGC030 is in very early-stage Phase 1 dose escalation with no interim data or binary catalyst on the calendar. Watch for any initial safety and pharmacokinetic data readouts, likely in late 2027 or 2028. The more impactful near-term catalyst for MGNX is the next MGC026 data update anticipated mid-2027. MGC030 alone is unlikely to move the stock meaningfully in the next 12 months.

Bull case
  • MGC030 is a novel antibody-drug conjugate (ADC) leveraging MacroGenics' proprietary ADC platform, which has shown encouraging data with the company's lead B7-H3 ADC MGC026 (27% best ORR in heavily pretreated SCCHN at ESMO 2026).
  • MacroGenics has $288M in cash with runway through 2028, providing ample funding to advance MGC030 through early-stage development without near-term dilution risk.
  • Analyst consensus skews bullish: 9 Buy/Strong Buy versus 5 Hold, with a mean price target of $8.00 (implying ~264% upside from the $2.20 close), and institutional accumulation was seen from BlackRock, FMR, and State Street in Q3.
Bear case
  • MGC030 is at the very beginning of clinical development (first patient dosed October 2026) with no efficacy data at all, making it a high-risk, long-duration asset with many failure points ahead.
  • The target antigen is undisclosed, making independent assessment of the drug's competitive positioning impossible for investors.
  • MacroGenics has no approved revenue-generating drugs; total revenues for the 9 months ended Sep 30, 2026 were $58M, down from $67M in the prior-year period, and the company relies on its $288M cash pile (runway through 2028) to fund operations.

Fresh Drug Report

This drug report is still fresh. Subscribe to read its impact, phase, bull and bear case and thesis.

Subscribe for Full Access

Other drugs in filings and trials

no drug report yet
  • MARGENZA Last: Approval · Dec 16, 2020

Past FDA events & how the stock moved

5 events
DateDrugEvent1 day5 days
Sep 30, 2026MGC030NDA filed−4.5%−5.8%
Apr 8, 2026lorigerlimabPartial clinical hold+2.7%+5.1%
Mar 9, 2026lorigerlimabPartial clinical hold+53.8%+39.0%
Feb 23, 2026lorigerlimabPartial clinical hold+1.8%+14.1%
Dec 16, 2020MARGENZAApproval−0.3%+2.1%

Clinical trials

1 Phase 2/3
DrugTrialPhaseStatusEnrolledPrimary completion
lorigerlimabA Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate CancerPhase 2Completed154Feb 19, 2026